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Abstract
Background: Neurocognitive impairments remain prevalent in HIV-1 infected individuals despite current antiretroviral
therapies. It is increasingly becoming evident that astrocytes play a critical role in HIV-1 neuropathogenesis
through the production of proinflammatory cytokines/chemokines. HIV-1 viral protein R (Vpr) plays an important
role in neuronal dysfunction; however, its role in neuroinflammation is not well characterized. The major objective
of this study was to determine the effect of Vpr in induction of proinflammatory chemokine CCL5 in astrocytes
and to define the underlying mechanism(s).
Methods: SVGA astrocytes were either mock transfected or were transfected with a plasmid encoding HIV-1 Vpr,
and the cells were harvested at different time intervals. The mRNA level of CCL5 expression was quantified using
real-time RT-PCR, and cell culture supernatants were assayed for CCL5 protein concentration. Immunocytochemistry
was performed on HIV-1 Vpr transfected astrocytes to check CCL5 expression. Various signaling mechanisms such as
p38 MAPK, PI3K/Akt, NF-κB and AP-1 were explored using specific chemical inhibitors and siRNAs.
Results: HIV-1 Vpr transfected astrocytes exhibited time-dependent induction of CCL5 as compared to mock-
transfected astrocytes at both the mRNA and protein level. Immunostained images of astrocytes transfected with HIV-1
Vpr also showed much higher accumulation of CCL5 in comparison to untransfected and mock-transfected astrocytes.
Pre-treatment with NF-κB (SC514) and PI3K/Akt (LY294002) inhibitor partially abrogated CCL5 mRNA and protein
expression levels as opposed to untreated controls after HIV-1 Vpr transfection. Specific siRNAs against p50 and
p65 subunits of NF-κB, p38δ MAPK, Akt-2 and Akt-3, and AP-1 transcription factor substantially inhibited the production
of CCL5 in HIV-1 Vpr transfected astrocytes.
Conclusion: These results demonstrate the ability of HIV-1 Vpr to induce CCL5 in astrocytes in a time-dependent
manner. Furthermore, this effect was observed to be mediated by transcription factors NF-κB and AP-1 and involved
the p38-MAPK and PI3K/Akt pathway.
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Introduction
HIV-1 enters the central nervous system (CNS) very
early in the course of the disease and causes productive
infection in the perivascular macrophages and microglia
of the brain [1-3]. HIV-associated neurocognitive disor-
ders or HAND is a common complication of nervous
system with HIV-1 infection and is comprised of cogni-
tive, motor and behavioral symptoms. The milder form
of neurocognitive impairment, minor cognitive motor
disorder (MCMD), remains prevalent in the HAART
era, affecting an estimated 40% − 50% of HIV-infected
individuals, while the more severe forms of dementia
have been substantially reduced [4]. The occurrence of
MCMD, despite the efficacy of HAART therapy in con-
trolling the viral load, suggests that the CNS viral load is
not the only factor determining the prevalence of HAND.
In fact, some studies suggest that glial activation shows
better correlation with the severity of HAND than the
amount of HIV replication in brain [5,6].
Astrocytes are the most abundant cell type in the brain
and play a primary role in the maintenance of homeostasis
in the brain. They regulate synaptic transmission, main-
tain the integrity of the blood–brain barrier (BBB) and
protect neurons by clearing toxic compounds [7]. HIV has
been shown to produce restricted infection of astrocytes
that can become productive in a supportive environment
[8,9]. Upon HIV entry into the CNS, microglial cells, peri-
vascular macrophages and astrocytes become activated
and release a myriad of neurotoxins such as quinolinic
acid, TGF-beta, TNF-α, MCP-1, RANTES/CCL5, IL-8, IP-
10 and NO [10-15]. The HIV-infected cells in the CNS
also release viral particles such as gp120 and Tat in the
brain microenvironment. These viral particles have been
demonstrated to elicit inflammatory responses from the
glial cells and have also been implicated in neuronal
apoptosis [16,17]. Given the abundance and importance
of astrocytes in the CNS, their dysregulation could have
profound and lasting consequences; for this reason,
these cells are widely believed to be a major cell type in-
volved in the progression of HAND. In fact, previous
work from our laboratory has demonstrated a role for
HIV-1 gp120 in the production of IL-6, IL-8 and CCL5
in astrocytes [18-20].
Viral protein R (Vpr) is a 96-amino-acid protein that
is highly conserved among lentiviruses. The role of Vpr
in HIV infection and replication is multifaceted and in-
cludes such functions as cell cycle arrest at the G2 phase,
transport of the pre-integration complex into the nucleus
and transactivation of HIV-1 long-terminal repeat [21-23].
The importance of Vpr in HIV pathogenesis is under-
scored by the findings that HIV infection in vitro is en-
hanced by Vpr [24,25]. Vpr has been found in the
different brain cell types including astrocytes of HAND
patients [26]. Some pathological changes associated with
Vpr in the brain include neuronal apoptosis, impaired
axonal growth, elevation of intracellular calcium and in-
creased production of reactive oxygen species in neur-
onal cells [27-29]. Furthermore, Vpr was recently shown
to induce IL-6 in monocyte-derived macrophages
(MDM), which can reactivate virus production from la-
tently infected cells [30].
CCL5, also known as RANTES, is a multifunctional
chemokine with evidence available for both harmful and
beneficial actions in the CNS. A study by Si et al. pro-
vided indirect evidence for the potential of Vpr to in-
duce RANTES/CCL5 in human microglial cells, where
Vpr deleted HIV-1 showed much lower levels of CCL5
when compared with intact HIV-1 containing Vpr [31].
Though the roles of Tat and gp120 have been extensively
studied, little work has been done on the role of Vpr on
the astrocytes. Given the potential role of Vpr in the ac-
tivation of astrocytes and microglial cells, it seems likely
that Vpr may play a critical role in the development of
HAND. In view of this, we sought to address the direct
effect of Vpr overexpression on the induction of chemo-
kine RANTES/CCL5 in astrocytes. In this report, we
also examined several distinct signaling mechanisms that
contributed to the induction of CCL5 in astrocytes.
Materials and methods
Cell culture and reagents
SVGA, a clone of the human fetal astrocytic cell line
(SVG) [32], was kindly provided by Dr. Avindra Nath.
These cells were maintained in Dulbecco’s modified Eagle
medium (DMEM, Cellgro) containing 10% FBS, 1% L-
glutamine, 1% non-essential amino acids, 1% sodium bi-
carbonate and gentamycin (50 μg/ml) in a humidified
incubator at 37°C and 5% CO2. Lipofectamine™ 2000 was
obtained from Invitrogen Inc. (Carlsbad, CA). Inhibitors
for NF-κB (SC514: IKK-β), P38/MAPK (SB203580), PI3K
(LY294002) and JNK (SP600125) were obtained from
Cayman Chemicals (Ann Arbor, MI, USA). Pre-designed
siRNAs for NF-κB (p50, p65), p38-MAPK (p38α, p38β,
p38γ, p38δ), Akt (Akt-1, Akt-2, Akt-3) and AP-1 were pur-
chased from Thermo Fisher Scientific Inc. (Waltham, MA).
All the experimental protocols used in this study were
approved by the Institutional Biosafety Committee (IBC)
at UMKC.
Construction of the HIV-1 Vpr plasmid
The Vpr expression plasmid was generated by amplifica-
tion of the Vpr sequence from HIV-1 IIIB for cloning into
the pcDNA3.1+ backbone. Briefly, H9/IIIB cells were cul-
tured for RNA isolation. RNA was reverse transcribed and
amplified by PCR using forward and reverse primers spe-
cific for the 5’ end (including the start codon) and 3’ end
(including a stop codon) of the Vpr coding sequence, re-
spectively. PCR product was verified by gel analysis and
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cloned directionally into pcDNA3.1D TOPO cloning vec-
tor (Invitrogen). Clones were sequenced to assess codon
integrity. The pcDNA3.1/Vpr96 clone was prepared for
transfection by the Endo Free Plasmid Mega kit (Qiagen)
using the standard protocol to obtain a high yield of endo-
toxin free plasmid.
Transfection
SVGA cells were transiently transfected with Lipofecta-
mine™ 2000 as per the manufacturer’s protocol. Briefly,
0.8 × 106 cells were incubated with 1 μg Vpr plasmid
and 4 μl of lipofectamine in 1 ml serum-free medium
for 5 h. The transfection was terminated by replacing
the transfection medium with an equal volume of complete
medium. The expression level of CCL5 was measured at 1,
3, 6, 12, 24, 48 and 72 h post transfection. For inhibition
experiments, the cells were treated with 10 μM inhibitor
(SB203580, LY294002, SP600125 and SC514) 1 h prior to
the transfection with the plasmid encoding Vpr. For siRNA
inhibition experiments, the cells were incubated for 24 h in
transfection medium with 50 nmol of siRNA, followed by
24 h of incubation in complete medium before transfection
with the plasmid encoding Vpr. For inhibitor and siRNA
experiments, the mRNA expression level of CCL5 was de-
termined at 6 h, while CCL5 protein levels were measured
at 48 h post-transfection. Mock-transfected cells were used
as a control to calculate the expression of CCL5.
Real-time RT-PCR and CCL5 protein determination
Total RNA was extracted from the SVGA cells using
RNeasy mini kits (QIAGEN, Valencia, CA) using the
manufacturer’s protocol. Then 150 ng of RNA was ampli-
fied using Bio-Rad iCycler using the primer sequences that
were commercially synthesized. The primer sequences for
CCL5 and PCR conditions used have been previously de-
scribed [19]. HPRT (hypoxanthine-guanine phosphoribo-
syl transferase) was used as a housekeeping control, and
the 2-ΔΔCt method was employed to calculate the expres-
sion levels of CCL5 [33]. The primer sequences and PCR
conditions for p38 and Akt isoforms used in this study
with slight modification have been previously described
[34,35]. The annealing temperatures of the primers were
selected based on their amplification in gradient PCR. The
annealing temperatures in this study were 57.5°C (Akt-1,
2, 3 and p38δ), 58°C (p38α and p38γ) and 59.7°C (p38β)
for 30 s.
The cell culture supernatants were centrifuged twice at
3,000 rpm and stored at −80°C. Centrifugation was done
to remove the cell debris that has the potential to block
the probe used in Bio-Plex system. The concentration of
extracellularly secreted cytokines in the supernatants was
measured by multiple cytokine assay kits (Bio-Rad,
Hercules, CA) using the manufacturer’s protocol and pre-
viously published method [19]. The CCL5 concentration
was determined based on 5PL standard curve using
Bio-Plex manager 5.0 software.
Agarose gel electrophoresis
The PCR products for p38 and Akt isoforms were elec-
trophoresed on 1.5% agarose gel for 1 h at 100 V. The gel
was stained with 0.005% ethidium bromide and was visu-
alized using the Alpha Innotech FluorChem® imager for
8 ms under UV light.
Immunocytochemistry
On glass cover slips, 0.6 × 106 cells were cultured in a
six-well plate and transfected with the plasmid encoding
Vpr. After 5 h, the transfection medium was replaced
with complete DMEM containing 1 mg/ml GolgiStop™
(BD Biosciences, San Jose, CA) to prevent the release of
CCL5. After 6 h, the cells were fixed with 1:1 ice-cold
methanol:acetone for 20 min at 20°C. The cells were
then permeabilized with PBST (PBS containing 0.1%
TritonX-100) and blocked with 1% BSA in PBST for
30 min at room temperature. The cells were washed 5×
with PBS after fixation and permeabilization. The cells
were incubated with a mixture of a rabbit polyclonal anti-
body to CCL5 (1:500; P230E, Thermo Scientific, Rockford
IL USA) and mouse MAb anti-GFAP (1:1,000; ab106509,
Abcam) overnight in a humidified chamber. The cells
were washed 5× with PBST and incubated with an anti-
rabbit antibody conjugated with Alexa Fluor 488 (1:1,000;
Cell Signaling Technology) and an anti-mouse antibody
conjugated with Alexa Fluor 555 (1:1,000; Cell Signaling
Technology) for 1 h at room temperature in the dark. All
the antibodies were diluted in 1% BSA containing PBS.
The cells were washed 5× with PBST and mounted on a
glass slide with 10 μl of Vectashield mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA).
The images were captured using Leica TCS SP5 II (Leica
Microsystems, Wetzler, Germany) on an inverted micro-
scope platform with 40× zoom lens. The intensity of
images was calculated using the Multi Measure tool
from NIH ImageJ software. The values were normalized
to GFAP.
Western blotting
SVGA astrocytes were either mock transfected or were
transfected with a plasmid encoding HIV-1 Vpr, and the
cells were harvested after 6 h, followed by the separation
of nuclear and cytosolic extracts using the NE-PER nu-
clear extraction kit (Pierce, Rockford, IL). Total cell ex-
tracts were prepared by adding RIPA buffer (Boston
Bioproducts, Ashland, MA). The lysates were homoge-
nized for 15 s and centrifuged at 14,000 × g for 15 min
to eliminate cell debris. Protein concentrations were de-
termined using the BCA protein assay kit (Pierce,
Rockford, IL), and 20 μg of protein was resolved on 10%
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SDS-PAGE (75 V for 3 h). For immunoblotting, proteins
were transferred (350 mA for 1.5 h) onto a PVDF mem-
brane and blocked overnight at 4°C with 5% nonfat milk
in PBST (PBS with 0.075% Tween 20). The membrane
was incubated with primary antibodies against p50 (Santa
Cruz Biotechnology Inc., 1:1,500) and c-fos (Cell Signaling
Technology, 1:1,500) for 3 h at room temperature and
washed 5× with PBST, followed by 2 h incubation in an
appropriate concentration of secondary antibodies conju-
gated to horseradish peroxide. The membrane was then
washed 5× with PBST, and the bands were visualized
using the BM chemiluminescence Western blotting sub-
strate (POD, Roche Applied Sciences; Indianapolis, IN).
FluorChem HD2 software (Alpha Innotech, San Leandro,
CA) was used for the quantification of the bands.
Statistical analysis
The results are expressed as mean ± SE for three inde-
pendent experiments with each experiment done in trip-
licate. The statistical significance was calculated using
Student’s t-test, and a p value ≤ 0.05 was considered
significant.
Results
Time-dependent induction of CCL5 by HIV-1 Vpr in SVGA
astrocytes
The expression levels of CCL5 are known to be in-
creased in the CSF of individuals suffering from HAND.
We transfected SVGA astrocytes with a plasmid encod-
ing HIV-1 Vpr using Lipofectamine 2000 reagent to as-
certain whether viral protein R has any role in increased
CCL5 expression. The transfection efficiency as deter-
mined by GFP transfection followed by BD FACScanto
flow cytometric analysis was in the range of 60-80%
(data not shown). CCL5 mRNA expression was deter-
mined at 1, 3, 6, 12, 24, 48 and 72 h post-transfection
(Figure 1A). The CCL5 mRNA expression level peaked
at 3 (24.43 ± 3.18-fold) and declined thereafter to reach
the basal level at 48 h. The increase in RNA level was
further confirmed by determining the protein concentra-
tions of CCL5 in cell culture supernatants. The superna-
tants were collected and analyzed at 6, 12, 24, 48 and
72 h after Vpr transfection of SVGA astrocytes (Figure 1B).
We observed significantly higher levels of CCL5 in Vpr-
transfected astrocytes compared to mock transfected at
time as low as 6 h. The CCL5 protein concentration was
higher at all time intervals analyzed, and the peak CCL5
concentration was seen at 48 h post transfection (2,040.5 ±
209.6 pg/ml) compared to mock-transfected controls
(200.7 ± 20.1 pg/ml).
Immunocytochemistry for HIV-1 Vpr-mediated induction
of CCL5 in SVGA astrocytes
In order to further confirm HIV-1 Vpr-mediated increased
expressions of CCL5, we performed immunocytochem-
istry on SVGA astrocytes after transfection with a plasmid
encoding Vpr. The cells were immunostained with a
cocktail of GFAP- and CCL5-specific antibodies. These
proteins were visualized by staining with secondary
antibodies conjugated to Alexa Fluor 488 (green) and
Alexa Fluor 555 (red) for CCL5 and GFAP, respectively.
DAPI staining was used to visualize the nuclei of the
cells. A representative staining is shown in Figure 2. A
strong yellow signal in the merged images signifying the
accumulation of CCL5 that was co-localized with GFAP
was seen in the astrocytes transfected with Vpr (Figure 2G-I)
as compared to mock-transfected (Figure 2D-F) or un-
transfected controls (Figure 2A-C). Our results also indi-
cated that mock transfection caused a slight but statistically
non-significant decrease in CCL5 expression (Figure 2J).
On the other hand, relative CCL5 expression in HIV-1



















































Figure 1 Time-dependent induction of CCL5 by HIV-1 Vpr in SVGA astrocytes. SVGA cells were mock transfected or transfected with a
plasmid encoding HIV-1 Vpr. Cells were harvested at 1, 3, 6, 12, 24, 48 and 72 h post-transfection, and CCL5 expression levels were determined
using real-time RT-PCR. The supernatants were also collected at 6, 12, 24, 48 and 72 h post-transfection, and protein concentration of CCL5 was
determined using Bioplex assay. (A) mRNA expression levels calculated relative to mock-transfected controls; (B) protein concentration for CCL5.
The bars represent the mean ± SE of three independent experiments done in triplicate. Statistical significance was determined using Student’s
t-test, **p < 0.01, *p < 0.05.
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compared to control and mock-transfected cells, re-
spectively (Figure 2J).
HIV-1 Vpr-mediated upregulation of CCL5 was abrogated
with inhibitor and siRNA against the NF-κB pathway
To identify the role of NF-κB in HIV-1 Vpr-mediated
upregulation of CCL5 in astrocytes, we tested SC514,
which is a specific inhibitor of NF-κB activation. The
concentration of inhibitor used was determined based
on IC50 values and its effect on cell viability (data not
shown). The cells were pre-treated 1 h with 10 μM of
SC514 before Vpr transfection, and the inhibitor was
present throughout the experiment. The CCL5 mRNA
expression and protein concentration were measured at
6 and 48 h post transfection, respectively (Figure 3A, B).
SC514 treatment significantly inhibited the production
of CCL5 at mRNA (8.85 ± 0.64-fold) and protein level
(1,681.9 ± 65.6 pg/ml) as compared to untreated controls
(13.15 ± 0.54-fold, 2,471.6 ± 110.9 pg/ml). To further
confirm the role of NF-κB, we transfected the cells with
siRNA against p50 and p65 subunits of NF-κB for 48 h
before transfecting them with a plasmid encoding Vpr
(Figure 3C, D). HIV-1 Vpr caused reduced CCL5 mRNA
expression in both p50 siRNA (2.4 ± 0.43-fold) and p65
siRNA (3.49 ± 0.61-fold) transfected cells as compared to
those cells transfected with scrambled siRNA (8.11 ± 1.82-
fold). We observed similar trend in the CCL5 protein
levels as well with p50 siRNA (540.42 ± 41.39 pg/ml) and
p65 siRNA (864.32 ± 77.43 pg/ml) showing statistically
significant reductions as compared to scrambled siRNA
transfected control (2,417.36 ± 553.39 pg/ml).
Involvement of the p38-MAPK and AP-1 pathway in HIV-1
Vpr-mediated induction of CCL5 in astrocytes
To dissect the upstream pathway involved in the pro-
duction of CCL5 after Vpr transfection of SVGA astro-
cytes, we tested the chemical inhibitors for the MAPK
(SP600125-JNK, SB203580-p38) pathway. The optimum
concentration of inhibitor was determined based on cell
viability and dose–response studies (data not shown).
The cells were pre-treated for 1 h with 10 μM of inhibi-
tors and then were either mock transfected or transfected
with a plasmid encoding Vpr. No significant reductions
(Figure 4A, B) were seen with either SP600125 (13.89 ±
0.85-fold, 2,919.9 ± 111.5 pg/ml) or SB203580 (22.89 ±
2.09-fold, 4,233.6 ± 433.3 pg/ml) as compared to untreated
controls (13.99 ± 1.65-fold, 2,946.92 ± 639.9 pg/ml). For
confirmation, SVGA cells were transfected with siRNA
against p38-MAPK (α, β, γ and δ) isoforms (Figure 4C,
D). Surprisingly, siRNA against the p38δ isoform showed
inhibition at both the mRNA (4.11 ± 0.42-fold) and pro-
tein (1,298.2 ± 40.96 pg/ml) levels, which was not seen
with chemical inhibitor against the p38 pathway. This was
in confirmation of a previous report that SB203580 in-
hibits only the α and β but not the γ and δ isoforms of the
p38 pathway [36]. In order to determine the specific silen-
cing effect of individual p38 isoform-specific siRNA, we
amplified the RNA from the cells depleted with different
p38 isoforms. The knockdown of the target was assessed
by resolving the product on agarose gel (Figure 4E) with
HPRT as a housekeeping control. To ascertain the down-
stream signaling molecule of p38δ MAPK, we transfected
the cells with siRNA against AP-1 transcription factor and
determined the effect of Vpr transfection at 6 h for mRNA
and 48 h for protein expression (Figure 4F, G). Statistically
significant reduction was seen with siRNA directed against
AP-1 at mRNA (4.43 ± 0.62-fold) and protein (1,598.34 ±
104.9 pg/ml) levels. This was further confirmed by deter-
mining the levels of c-fos, one of the major subunits of
AP-1, after the transfection with p38δ-specific siRNA
Figure 2 Immunocytochemistry for HIV-1 Vpr-mediated induction
of CCL5 in astrocytes. SVGA astrocytes were cultured on cover slips
and were either mock transfected (D-F) or were transfected with a
plasmid encoding Vpr (G-I). Non-transfected cells were used as control
(A-C). The cells were stained for nucleus (blue); CCL5 (green) and GFAP
(red), and the images were captured using a Leica TCS SP5 II on an
inverted microscope platform with a 40× zoom oil emersion lens. The
Image J software was used to get the merged images, and the Multi
Measure tool in Image J was used to quantify the intensities. (J) The
image intensities are plotted relative to GFAP. The bars represent the
mean ± SE of three independent images. Statistical significance was
determined using Student’s t-test, **p < 0.01.
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(Figure 4H). The transfection of HIV-1 Vpr in astrocytes
led to an increase in the levels of c-fos, which was partially
reversed by p38δ-specific siRNA but not with scrambled
siRNA.
PI3K/Akt-mediated activation of NF-κB plays a role in the
HIV-1 Vpr-mediated expression of CCL5 in SVGA
astrocytes
To understand the upstream signaling responsible for
the activation of NF-κB in HIV-1 Vpr-mediated induc-
tion of CCL5 in astrocytes, we pre-treated the cells with
the PI3K/Akt inhibitor LY294002 (10 μM). The optimal
dose concentration was determined based on the dose–
response and cell viability studies. Pre-treatment with
LY294002 (Figure 5A, B) substantially reduced the expres-
sion of CCL5 (9.02 ± 1.30-fold, 1,188.8 ± 343.1 pg/ml)
as compared to untreated controls (13.99 ± 1.65-fold,
2,946.92 ± 639.9 pg/ml) after transfection of astrocytes
with HIV-1 Vpr. Further, to corroborate the inhibition
seen with LY294002, we transfected Vpr into the cells
that were already transfected with siRNA against Akt
isoforms (Akt-1, Akt-2 and Akt-3) or scrambled control
(Figure 5C, D). The astrocytes transfected with siRNAs
that targeted Akt-2 (3.83 ± 0.64-fold; 1,742.8 ± 82.6 pg/ml)
and Akt-3 (3.54 ± 0.53-fold; 1,408.2 ± 150.8 pg/ml) showed
significant abrogation of CCL5 at both the mRNA and
protein levels as compared to scrambled siRNA-transfected
control (6.26 ± 0.31-fold, 2,158.9 ± 257.5 pg/ml) after Vpr
transfection. The slight inhibition seen with Akt-1 isoform
(5.69 ± 0.38-fold; 1,846.3 ± 274.1 pg/ml) was not statistically
significant. Specificity of the siRNAs for Akt isoforms was
determined by amplifying the silenced RNA using Akt
isoform-specific primers. The products were then resolved
on the agarose gel, stained with ethidium bromide and
visualized under UV light (Figure 5E). Amplification of
HPRT was used as a housekeeping control.
To confirm whether PI3K/Akt signaling is involved in
the activation NF-κB, LY294002-treated cells were ana-
lyzed for the translocation of p50 from cytosol to nucleus.
PI3K/Akt inhibition by LY294002 substantially reduced
p50 translocation as compared to inhibitor-untreated con-
trols (Figure 5F). This clearly demonstrates that NF-κB ac-
tivation in response to HIV-1 Vpr was mediated though
PI3K/Akt signaling. The schematic representation (Figure 6)
depicts that HIV-1 Vpr induces the expression of CCL5 in
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Figure 3 Involvement of NF-κB in HIV-1 Vpr-mediated upregulation of CCL5 in astrocytes. SVGA astrocytes were pre-treated with the
chemical inhibitors or transfected with siRNA targeting the NF-κB pathway, followed by mock transfection or transfection with a plasmid encoding
Vpr. (A) and (B) Effect of chemical inhibitor of the NF-κB pathway, SC514 on mRNA expression and protein concentration for CCL5, respectively.
(C) and (D) Effect of siRNA against p50 and p65 subunits of NF-κB on CCL5 mRNA expression and protein concentration, respectively. The bars
represent the mean ± SE of three independent experiments done in triplicate. Statistical significance was determined using Student’s t-test,
**p < 0.01, *p < 0.05.
Gangwani et al. Journal of Neuroinflammation 2013, 10:136 Page 6 of 12
http://www.jneuroinflammation.com/content/10/1/136
Figure 4 (See legend on next page.)
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NF-κB and AP-1 through the involvement of signaling in-
termediates PI3K/Akt and p38δ, respectively.
Discussion
The primary goal of this study was to determine the ef-
fect of HIV-1 Vpr on the CCL5 expression in astrocytes
and to unravel the underlying mechanism(s). In addition
to CCL5, we also analyzed the expressions of TNF-α and
IL-1β in the astrocytes with HIV-1 Vpr in real-time RT-
PCR and multiple cytokine assay. However, these cyto-
kines were generally found to be unaffected by HIV-1
Vpr and thus were not considered for further studies.
HIV-1 Vpr is known to be apoptogenic and has been im-
plicated in apoptosis of a variety of cell types including
T-cells, neurons and astrocytes [37-39]. Vpr is shown to
play a role in neuroinflammation associated with HIV-1
by inducing the production of many neurotoxins such as
IL-6, IL-8 and ROS [30,40]. The importance of Vpr in
CCL5 induction is highlighted by the fact that Vpr-
deleted HIV-1 produces much lower amounts CCL5 as
compared to the intact HIV-1 in microglial cells [31].
Our results have unequivocally shown that HIV-1 Vpr
induces the production of CCL5 in astrocytes in a time-
dependent manner at both RNA and protein levels.
CCL5 is widely established as a proinflammatory chemo-
kine and has been shown to be involved in neuroinflam-
matory conditions. However, in the context of HIV-1
infection, its role has been contradictory. CCL5 at higher
concentrations ranging from 500 ng/ml to 5 μg/ml in-
creases the permissibility of cells to HIV infection [41].
On the other hand, CCL5 at 200 ng/ml – 500 ng/ml is
shown to protect the neuronal cells from HIV-1 gp120-
mediated cell death [42,43]. Also CCL5 treatment of the
differentiated neuronal cell line at 300 ng/ml has been
shown to upregulate genes involved in neuronal survival
and neurite outgrowth [44]. The CCL5 concentration
found in many neuropathological settings and consid-
ered as neurotoxic is below 50 ng/ml. In fact, it has been
shown that 50 ng/ml CCL5 induces apoptosis in neuro-
blastoma cells [45]. We found a CCL5 concentration of
2–3 ng/ml at peak induction after introduction of Vpr in
astrocytes, which might be closely related to neuroin-
flammatory as opposed to the neuroprotective scenario.
In T-cells, CCL5 has been shown to be present in
unique storage vesicles and rapidly released after T-cell
activation [46]. However, in our experimental conditions,
CCL5 was observed to be secretory soon after produc-
tion as we detected significant concentration of CCL5
within 6 h. Therefore, It seems that the CCL5 storage
phenomenon in distinct secretory compartments may be
cell-type specific.
NF-κB is a ubiquitous transcription factor, involved in
the regulation of myriad of inflammatory genes as well
as cell survival signaling pathways. It plays an essential
role in the expression of the CCL5 gene as well [47]. To
explore the possibility of involvement of NF-κB in CCL5
induction by HIV-1 Vpr in astrocytes, we employed
SC514, which is a specific inhibitor for the IKK-2 path-
way of NF-κB activation [48]. IKKs are upstream kinases
responsible for phosphorylation and proteasomal deg-
radation of IκB-α and subsequent activation of NF-κB.
NF-κB complex consists of p50 and p65 subunits at-
tached to inhibitory IκB-α, which retains them in the
cytosol. This complex gets activated by the removal of
IκB-α, translocates to the nucleus and binds to the pro-
moter regions of specific genes [49]. The reduction in
CCL5 expression by SC514 therefore confirms the in-
volvement of the NF-κB pathway in HIV-1 Vpr-mediated
production of CCL5 in astrocytes. Our results using p50-
and p65-specific siRNA also demonstrate the direct in-
volvement of NF-κB in CCL5 expression.
Recently, it has been reported that CCL5 expression in
astrocytes can be blocked by the inhibitors of the MAPK
and PI3K pathway [50]. The CCL5 promoter contains
binding sites not only for NF-κB, but also for CREB
(cAMP response element-binding protein), AP-1 (activa-
tor protein 1), C/EBP (CCAAT/enhancer binding pro-
tein) and IRF (interferon regulatory factor) [51]. These
transcription factors are known to involve upstream sig-
naling through the MAPK and PI3K/Akt pathway. In
this study, the treatment of astrocytes with LY294002
(PI3K/Akt) but not with SB203580 (p38 MAPK) and
SP600125 (JNK MAPK) inhibited the CCL5 expression
in response to HIV-1 Vpr. These results clearly suggest
that PI3K/Akt but not JNK/MAPK is involved in NF-κB
activation in our system. In our attempt to further dis-
sect the involvement of PI3K/Akt, we employed Akt-
specific siRNAs. Akt, also known as protein kinase B, is
(See figure on previous page.)
Figure 4 Role of p38-MAPK and AP-1 in HIV-1 Vpr-mediated induction of CCL5 in astrocytes. SVGA astrocytes were pre-treated with the
chemical inhibitors for the JNK-MAPK (SP600125) and p38-MAPK (SB203580) pathway 1 h before mock transfection or transfection with a plasmid
encoding HIV-1 Vpr. (A) and (B) Effect of chemical inhibitors on mRNA expression and protein concentration for CCL5, respectively. SVGA cells
were also transfected with siRNA targeting p38 isoforms (α, β, γ, δ) and AP-1 followed by mock transfection or transfection with a plasmid encoding
Vpr. (C) and (F) Effect of siRNAs on CCL5 mRNA expression; (D) and (G) effect on CCL5 protein concentration, respectively. (E) Specificity of p38
isoform siRNAs against respective subunits; (H) inhibition of AP-1 (c-fos) with the siRNA directed toward the p38δ subunit of p38-MAPK. The
bars represent the mean ± SE of three independent experiments done in triplicate. Statistical significance was determined using Student’s t-test,
**p < 0.01, *p < 0.05.
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a family of serine/threonine kinases comprising three iso-
forms, Akt-1, Akt-2 and Akt-3. They differ from each
other in only one amino acid residue in their phosphoryl-
ation/activation site, Akt-1 (ser-473, thr-308), Akt-2 (ser-
474, thr-309) and Akt-3 (ser-472, thr-305) [52]. They also
differ in their subcellular localization in a tissue-specific
manner, with Akt-3 being the most abundant isoform in
the brain [52,53]. It has been shown that Akt-3-deficient
mice have smaller brains with suppressed inflammatory






Figure 5 Activation of NF-κB involves PI3K/Akt signaling in HIV-1 Vpr-mediated induction of CCL5 in astrocytes. SVGA astrocytes were
pre-treated with the chemical inhibitor for the PI3K/Akt pathway (LY294002) 1 h before mock transfection or transfection with a plasmid encoding
HIV-1 Vpr. (A) and (B) Effect of LY294002 on mRNA expression and protein concentration for CCL5, respectively. SVGA cells were also transfected
with siRNA targeting Akt isoforms (Akt-1, Akt-2 and Akt-3) followed by mock transfection or transfection with a plasmid encoding Vpr. (C) and
(D) Effect of siRNAs on CCL5 mRNA expression and protein concentration, respectively. (E) Specificity of siRNA for Akt isoforms against individual
subunits. (F) Inhibition of NF-κB (p50) nuclear translocation with LY294002. The bars represent the mean ± SE of three independent experiments
done in triplicate. Statistical significance was determined using Student’s t-test, **p < 0.01, *p < 0.05
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[53,54]. Recently, Akt-2 deficient macrophages have been
shown to be hyporesponsive to LPS and produce lower
levels of IL-6 and TNF-α [53]. In our study, siRNA medi-
ated knockdown of Akt-2 and Akt-3 isoforms but not
Akt-1 showed suppression of CCL5, which is in consistent
with earlier reports that Akt-2 and Akt-3 play an import-
ant role in regulation of cytokine gene expression [54,55].
Our results showing only partial abrogation of CCL5
expression by SC514, LY294002, sip50 and sip65 suggest
the possibility that other signaling mechanisms are also
involved in HIV-1 Vpr-mediated CCL5 upregulation.
Therefore, we explored various p38 MAP kinases. There
are four isoforms of the p38-MAPK pathway, p38α,
p38β, p38γ and p38δ, which can be activated by stress
and are distributed in a tissue-specific manner. SB203580
(a p38 chemical inhibitor) did not show any CCL5 in-
hibition, but it is a known inhibitor of only p38α and
p38β isoforms with no or minimal inhibition at higher
concentrations on p38γ and p38δ isoforms [36]. We
therefore used siRNAs against each p38 isoform. Our
results with p38δ siRNA raised the possibility of in-
volvement of another transcription factor (AP-1) be-
cause the CCL5 promoter contains an AP-1 responsive
element and has been shown to be involved in the
production of CCL5 [47]. This was confirmed by
siRNA-mediated AP-1 knockdown. The p38δ and AP-1
connection has been shown in other systems as
well, as it has been shown to regulate keratinocyte
differentiation through the AP-1 transcription factor [56].
Furthermore, synthetic Vpr protein has been shown to
activate AP-1, which in turn stimulates HIV-1 transcrip-
tion in monocytes and macrophages [57]. We also found
the reduction in the expression of c-fos subunit of AP-1
with the siRNA directed against p38δ. This clearly
demonstrates the involvement of AP-1 in HIV-1
Vpr-mediated induction of CCL5 in astrocytes. Further,
the activation and nuclear translocation of the p50 sub-
unit of NF-κB involved PI3K/Akt signaling were illus-
trated with the reduction of p50 nuclear levels in the
presence of LY294002. This provides direct evidence for
the involvement of PI3K/Akt in the activation of NF-κB
with the transfection of astrocytes with HIV-1 Vpr. Our
studies are in accordance with the previous report sug-
gesting the involvement of HIV-1 Vpr in the activation
of transcription factors such as NF-κB and AP-1 in pri-
mary macrophages [57].
Conclusions
In summary, we have shown that HIV-1 Vpr induces
CCL5 expression in astrocytes in a time-dependent man-
ner. Furthermore, CCL5 expression involved the tran-
scription factors NF-κB and AP-1. AP-1 was shown to
be activated by p38δ, while NF-κB activation involved
signaling through the PI3K/Akt pathway (Figure 6).
These studies are important for the development of ad-
junct therapy as we have identified different steps that
could be targeted to suppress CCL5 expression.
Figure 6 Schematic of the signaling pathways involved in the induction of CCL5 by HIV-1 Vpr in astrocytes. HIV-1 Vpr activates p38-
MAPK- and PI3K/Akt-related signaling pathways in SVGA astrocytes leading to the activation of transcription factors AP-1 and NF-κB, respectively.
NF-κB and AP-1 bind to the promoter region of CCL5 and increase its production in astrocytes. Blue color represents the use of chemical inhibitor,
while green color represents the use of siRNA. Involvement of particular signaling is shown in darker shades, while lighter shades imply
no involvement.
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